All articles by Manish Kumar
GRIN Therapeutics receives FDA breakthrough therapy designation for Radiprodil
Designation for treatment of seizures associated with GRIN-related neurodevelopmental disorder in patients with gain-of-function mutations recognizes radiprodil’s potential to demonstrate substantial improvement over available symptom-based therapy
Samsung Bioepis launches Stelara biosimilar Pyzchiva in US
Pyzchiva has been approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn’s disease and ulcerative colitis
Takeda wins EMA approval for new subcutaneous option of Takhzyro
The new subcutaneous treatment option for HAE will offer personalised care to reduce disease burden and enhance patients’ quality of life
Mirum wins FDA approval for Ctexli to treat cerebrotendinous xanthomatosis
The FDA approval of Ctexli was based on the RESTORE trial, which met the primary endpoint and showed a significant reduction in bile alcohols
Illumina and Broad Clinical Labs usher in new era of drug discovery
Longstanding partners bring together end-to-end workflows and leading CRISPR
Perturb-seq technologies setting a standard for single-cell studies and enabling a 5
billion single-cell atlas ecosystem within three years
Eva and Sanofi report positive results for Duvakitug in Phase 2b IBD trial
New data from the RELIEVE UCCD study support the efficacy and safety of Duvakitug across all pre-specified subgroups and doses
Amneal announces Mesalamine launch, FDA approval for Lenalidomide
Lenalidomide, available in strengths ranging from 2.5mg to 25mg, is a thalidomide analogue used to treat various blood cancers, including multiple myeloma and transfusion-dependent anaemia
X4 Pharmaceuticals and Taiba Rare sign distribution deal for Xolremdi
Taiba Rare will lead Xolremdi distribution and marketing, collaborating with X4 on strategies across Saudi Arabia, the UAE, Qatar, Oman, Kuwait, Bahrain, and Egypt
Nona announces licensing agreement with the University of Alabama
Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions
Cumberland’s Vibativ receives NMPA approval for distribution in China
Vibativ is an injectable antibiotic for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections, including MRSA